Home > Browse Issues > Vol.44 No.1
Recent Progress in the Biology of Multiple Myeloma
HAO Mu*, QIU Lugui
(State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China)
Abstract:
Over the past 20 years, novel agents have led to a significant improvement in survival of patients with MM (multiple myeloma), with overall survival increasing from 2-3 years to 8-10 years. The in-depth understanding of MM tumor biology has promoted the progression of clinical diagnosis, prognosis evaluation and therapeutic effect. It also provides biological basis and new targets for the development of molecular targeted anti-MM drugs and immunotherapy strategies. Unfortunately, MM is still an incurable malignancy so far. Here, the research progression of MM biology is reviewed.
CN
EN